Novo Nordisk launches new initiative to prevent childhood obesity in disadvantaged urban communities
- Details
- Category: Novo Nordisk

Calquence granted Priority Review in the US for patients with untreated mantle cell lymphoma
- Details
- Category: AstraZeneca

The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer significant improvements over available options by demonstrating safety or efficacy improvements, preventing serious conditions or enhancing patient compliance.
BlueRock Therapeutics' investigational cell therapy bemdaneprocel for Parkinson's disease shows positive data at 24-months
- Details
- Category: Bayer

Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson's disease.
Bayer Co.Lab Shanghai opens as part of global expansion of life science incubator network
- Details
- Category: Bayer

FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis
- Details
- Category: Roche

Pfizer highlights diverse oncology oortfolio and combination approaches at ESMO 2024
- Details
- Category: Pfizer

Bayer and NextRNA Therapeutics enter strategic collaboration to develop small molecules targeting long non-coding RNAs (lncRNAs) in oncology
- Details
- Category: Bayer

More Pharma News ...
- Pfizer launches PfizerForAll™, a digital platform that helps simplify access to healthcare
- Pfizer and BioNTech provide update on mRNA-based combination vaccine program against influenza and COVID-19 in individuals 18-64 years of age
- Pfizer announces top-line results of ABRYSVO® for RSV in immunocompromised adults
- Novartis receives FDA accelerated approval for Fabhalta® (iptacopan)
- Vividion Therapeutics to expand with new global research and development center
- Pfizer announces positive topline results From Phase 3 study of hemophilia A gene therapy candidate
- Darolutamide meets primary endpoint in Phase III ARANOTE trial